A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data

被引：0
|
作者：
Schneeweiss, Andreas
Ruiz, Amparo
Manikhas, Alexey
Bottini, Alberto
Rovira, Pedro Sanchez
Mansouri, Kambiz
Kazeem, Gbenga
Bauknecht, Thomas
机构：
[1] Univ Heidelberg Hosp, Heidelberg, Germany
[2] Inst Valenciano Oncol, Valencia, Spain
[3] City Clin Oncol Dispensary, St Petersburg, Russia
[4] AO Ist Ospitalieri, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[5] Complejo Hosp Jaen, Jaen, Spain
[6] Lilly Deutschland GmbH, Bad Homburg, Germany
[7] Lilly United Kingdom, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
    L. G. Estévez
    P. Sánchez-Rovira
    M. Dómine
    A. León
    I. Calvo
    A. Jaén
    V. Casado
    G. Rubio
    M. Díaz
    C. Miró
    F. Lobo
    E. Carrasco
    M. Casillas
    B. San Antonio
    [J]. Clinical and Translational Oncology, 2007, 9 : 317 - 322
  • [32] Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
    Ganem, G
    Tubiana-Hulin, M
    Fumoleau, P
    Combe, M
    Misset, JL
    Vannetzel, JM
    Bachelot, T
    De Ybarlucea, LR
    Lotz, V
    Bendahmane, B
    Dieras, V
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (11) : 1623 - 1628
  • [33] Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial
    Jiao, Dechuang
    Qiao, Jianghua
    Wang, Chengzheng
    Li, Juntao
    Sun, Xianfu
    Lu, Zhenduo
    Zhang, Chongjian
    Li, Lianfang
    Yan, Min
    Feng, Yueqing
    Zhou, Yong
    Deng, Miao
    Liu, Xinlan
    Ma, Mingde
    Jia, Haiquan
    Xia, Qingxin
    Chen, Xiuchun
    Liu, Zhenzhen
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [34] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    [J]. CANCER RESEARCH, 2017, 77
  • [35] Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
    Zhang, Liulu
    Wu, Zhiyong
    Lin, Ying
    Li, Jie
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ci-Qiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
    Loesch, D. M.
    Greco, F.
    O'Shaughnessy, J.
    Hainsworth, J. D.
    Vukelja, S. J.
    Sandbach, J.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    Robert, N. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Silvia Antolín
    Ramón Mel
    Manuel Ramos
    Andrés García-Palomo
    Concepción Almanza
    Laura de Paz
    Lourdes Calvo
    Elena Álvarez
    Ana González
    Jesús García-Mata
    [J]. Clinical and Translational Oncology, 2011, 13 : 686 - 691
  • [38] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Antolin, Silvia
    Mel, Ramon
    Ramos, Manuel
    Garcia-Palomo, Andres
    Almanza, Concepcion
    de Paz, Laura
    Calvo, Lourdes
    Alvarez, Elena
    Gonzalez, Ana
    Garcia-Mata, Jesus
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (09): : 686 - 691
  • [39] Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer
    Pernas Simon, S.
    Rezai, M.
    Hauschild, M.
    Machiels, J. P.
    Paepke, S.
    Llombart Cussac, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [40] Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer
    Ramaswamy, B
    Povoski, SP
    Rhoades, C
    Allen, J
    Hauger, M
    Young, D
    Burak, W
    Farrar, W
    Yee, L
    Kendra, K
    Somasundaram, S
    Orlowski, RZ
    Shapiro, CL
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) : 67 - 74
12345